» Articles » PMID: 36091062

Systemic Consequences of Abnormal Cholesterol Handling: Interdependent Pathways of Inflammation and Dyslipidemia

Overview
Journal Front Immunol
Date 2022 Sep 12
PMID 36091062
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic conditions such as obesity and associated comorbidities are increasing in prevalence worldwide. In chronically inflamed pathologies, metabolic conditions are linked to early onset cardiovascular disease, which remains the leading cause of death despite decades of research. In recent years, studies focused on the interdependent pathways connecting metabolism and the immune response have highlighted that dysregulated cholesterol trafficking instigates an overactive, systemic inflammatory response, thereby perpetuating early development of cardiovascular disease. In this review, we will discuss the overlapping pathways connecting cholesterol trafficking with innate immunity and present evidence that cholesterol accumulation in the bone marrow may drive systemic inflammation in chronically inflamed pathologies. Lastly, we will review the current therapeutic strategies that target both inflammation and cholesterol transport, and how biologic therapy restores lipoprotein function and mitigates the immune response.

Citing Articles

Dyslipidemia induced inflammation mediated the association between obesity and Osteoarthritis: a population-based study.

Yan L, Ge H, Xu Q, Jiang D, Shen A, Yang M BMC Public Health. 2024; 24(1):3155.

PMID: 39538170 PMC: 11562305. DOI: 10.1186/s12889-024-20616-4.


Effects of Regular Exercise on the Biochemical, Oxidative, and Inflammatory Profiles and Quality of Life in Older Spaniards with Metabolic Syndrome.

Monserrat-Mesquida M, Quetglas-Llabres M, Bouzas C, Garcia S, Mateos D, Ugarriza L Antioxidants (Basel). 2024; 13(4).

PMID: 38671898 PMC: 11047339. DOI: 10.3390/antiox13040450.


Association between vitamin D levels and risk of periodontitis in patients with metabolic syndrome.

Liang Z, Zhang Y, Li G J Dent Sci. 2024; 19(2):1012-1020.

PMID: 38618072 PMC: 11010607. DOI: 10.1016/j.jds.2023.06.026.


Trafficking and effect of released DNA on cGAS-STING signaling pathway and cardiovascular disease.

Zhou Z, Ou-Yang C, Chen Q, Ren Z, Guo X, Lei M Front Immunol. 2023; 14:1287130.

PMID: 38152400 PMC: 10751357. DOI: 10.3389/fimmu.2023.1287130.


Dyslipidemia is not associated with interferon-regulated chemokines or disease activity in systemic lupus erythematosus.

Hernandez-Solano L, Amezcua-Castillo E, Amezcua-Guerra L Clin Rheumatol. 2023; 42(7):1993-1995.

PMID: 37178267 DOI: 10.1007/s10067-023-06631-7.


References
1.
Tavori H, Fenton A, Plubell D, Rosario S, Yerkes E, Gasik R . Elevated Lipoprotein(a) Levels Lower ABCA1 Cholesterol Efflux Capacity. J Clin Endocrinol Metab. 2019; 104(10):4793-4803. PMC: 6735736. DOI: 10.1210/jc.2018-02708. View

2.
Pappu R, Schwab S, Cornelissen I, Pereira J, Regard J, Xu Y . Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007; 316(5822):295-8. DOI: 10.1126/science.1139221. View

3.
Liao K, Playford M, Frits M, Coblyn J, Iannaccone C, Weinblatt M . The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc. 2015; 4(2). PMC: 4345878. DOI: 10.1161/JAHA.114.001588. View

4.
Ridker P, Everett B, Thuren T, MacFadyen J, Chang W, Ballantyne C . Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017; 377(12):1119-1131. DOI: 10.1056/NEJMoa1707914. View

5.
Koh J, Yoon S, Kim M, Cho S, Lim J, Park Y . Lipidome profile predictive of disease evolution and activity in rheumatoid arthritis. Exp Mol Med. 2022; 54(2):143-155. PMC: 8894401. DOI: 10.1038/s12276-022-00725-z. View